EpimAb Biotherapeutics announced Wednesday that it has raised $74 million in its Series B funding, extending the streak of private fundraising among Chinese biopharmaceutical firms specialising in anti-cancer drug research.
The Shanghai-based company said the funding was co-led by SDIC Fund, the investment arm of State Development Investment Corporation, and Beijing-based venture capital firm Sherpa Healthcare Partners.
Wednesday’s announcement came slightly more than two years after EpimAb’s Series A funding round in April 2017, through which it raised $25 million from the likes of Oriza Ventures, Decheng Capital and 3E Bioventures.
The three-year-old startup is the latest in a long list of...
¬ Haymarket Media Limited. All rights reserved.
